Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.
Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results